REPORT HIGHLIGHT
Hepatitis therapeutics market was valued at USD 21.86 billion by 2019, growing with 2.6% CAGR during the forecast period, 2020-2026.

Hepatitis can be defined as an inflammation of the liver, which is caused due to a viral infection. It is one of the leading causes of health care burden in both developing as well as developed countries. Hepatitis can progress to scarring (fibrosis), cirrhosis, liver cancer or it can be self-limiting. The major causes of hepatitis are hepatitis viruses and the heavy consumption of alcohol, which affects the liver. However, autoimmune diseases and toxic substances can also cause hepatitis.

Market Dynamics

The rising prevalence of viral hepatitis, an increase in healthcare expenditure, and a surge in the number of autoimmune diseases are the major factors boosting the growth of the global hepatitis therapeutics market. According to the statistics provided by the World Health Organization (WHO), around 325 million people were diagnosed with viral hepatitis worldwide in 2016 and this number is expected to increase by 2030. Moreover, the growing usage of infected syringes and unsterilized equipment, transfusion of infectious blood, and medication errors are other factors propelling the market growth.

In addition, high success rates of pipeline drugs, the increase in consumption of alcohol, and the growing incidence of liver diseases will impel the market growth in upcoming years. However, high development costs and stringent reimbursement policies are predicted to hinder the growth of the global market. On the contrary, the growing development in advanced therapies and increasing focus towards retaining the best quality life are expected to create lucrative growth opportunities in the overall market during the forecast period.

Disease Type Takeaway

“Hepatitis B segment to be most lucrative during the forecast period”

Based on the disease type, the global market for hepatitis therapeutics is categorized into hepatitis A, B, and C. Among these, the hepatitis B (HBV) segment accounted for the majority of market share in 2019 and is expected to lead the market during the forecast period. This is majorly because the virus can be easily transmitted through body fluids and blood of an infected person. The prevalence of hepatitis B is high all across the globe, which is driving the segmental market growth. According to the WHO, around 27 million people all across the globe were aware of HBV infection, of which 4.5 million diagnosed were on treatment in 2016.

On the other hand, the hepatitis C (HCV) segment is estimated to grow at a considerable rate during the forecast period due to the growing prevalence of liver diseases all over the world. WHO statistics reveal that about 71 million people worldwide were living with the HCV infection in 2016.

Drug Class Takeaway

“Multi-class combination segment to dominate the industry by 2026”

On the basis of drug class, the worldwide hepatitis therapeutics market is categorized into NS5A inhibitor, interferon & ribavirin, multi-class combination, and nucleotide analog NS5B polymerase inhibitor. Of these, the NS5A inhibitor accounted for the largest market share in 2019 and is anticipated to grow at a significant rate during the forecast period. This is mainly because it is the most common drug used for the treatment of viral hepatitis. In addition, the increasing consumption of alcohol is resulting in liver diseases, which is resulting in increased demand for NS5A inhibitor all across the globe. On the other hand, the multi-class combination segment is estimated to grow at a significant rate during the forecast period owing to its favorable features such as effectiveness across the genotypes of Hepatitis C.

Distribution Channel

“Hospital pharmacies segment to grow at a significant rate throughout the forecast”

Based on the distribution channel, the worldwide hepatitis therapeutics market is classified into online pharmacies, retail pharmacies, and hospital pharmacies. Of these, the hospital pharmacies segment is estimated to lead the market during the forecast period. The dominance of this segment is mainly because the dispensations of drugs at these pharmacies ensure a greater deal of safety. On the other hand, the retail pharmacies segment is estimated to be the second-largest market at a significant rate during the forecast period.

COVID-19 Impact

The emergence of the life-threatening COVID-19 has brought the world to a halt. This health crisis has brought an uncertain impact on businesses across various industries. The global hepatitis therapeutic market is adversely affected due to the COVID-19 pandemic. However, the rising support from governments and various strategies adopted by the companies is helping to fight against this highly contagious disease. The overall market is expected to witness an impressive growth post the coronavirus pandemic.

Key Vendor Takeaway

The leading players of the global hepatitis therapeutics market include Merck, Johnson & Johnson, Biocon, Bristol-Myers Squibb Co, Gilead Lifesciences, NATCO Pharma Limited, ZydusCadila, Hetero Healthcare, Roche Diagnostics, LAURUS Labs, Cipla, Inc., and AbbVie.

In November 2019, Gilead Sciences announced new data from the Viral Hepatitis Research Programs at The Liver Meeting.® The new data of the Vemlidy® (tenofovir alafenamide 25 mg, TAF) continues to support an enhanced safety profile compared with tenofovir disoproxil fumarate (TDF) in patients with chronic HBV (Hepatitis B) infection.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year – 2015 to2018
Base Year – 2019
Estimated Year – 2020
Projected Year – 2026
TARGET AUDIENCE

Traders, Distributors, and Suppliers
Manufacturers
Government and Regional Agencies
Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HEPATITIS THERAPEUTIC MARKET KEY PLAYERS

NATCO Pharma Limited
ZydusCadila
Hetero Healthcare
Merck & Co.
Gilead Lifesciences
Roche Diagnostics
LAURUS Labs
Cipla, Inc.
Johnson & Johnson
Biocon Limited
Bristol-Myers Squibb Co
AbbVie, Inc.
GLOBAL HEPATITIS THERAPEUTIC MARKET, BY DISEASE TYPE

Hepatitis A
Hepatitis B
Hepatitis C
Others
GLOBAL HEPATITIS THERAPEUTIC MARKET, BY DRUG CLASS

Nucleotide Analog NS5B Polymerase Inhibitor
NS5A Inhibitor
Multi-Class Combination
Interferon & Ribavirin
Others
GLOBAL HEPATITIS THERAPEUTIC MARKET, BY DISTRIBUTION CHANNEL

Online Pharmacies
Retail Pharmacies
Hospital Pharmacies
GLOBAL HEPATITIS THERAPEUTIC MARKET, BY REGION

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Singapore
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Rest of MEA